Targeting the tumor vasculature to improve the efficacy of oncolytic virus therapy.
Rhim
Jung Hyo
JH
Tosato
Giovanna
G
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D002448:Cell Adhesion / Q000187:drug effects; D004195:Disease Models, Animal; D005910:Glioma / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D050130:Oncolytic Virotherapy; D010456:Peptides, Cyclic / Q000494:pharmacology*; D051381:Rats; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D010456:Peptides, Cyclic; D042461:Vascular Endothelial Growth Factor A; C507169:cyclic arginine-glycine-aspartic acid peptide